Treatment of childhood Plasmodium falciparum malaria: Current challenges

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 1, 2007, Pages 141-152

  Bell, David J ^a,b   Molyneux, Malcolm E ^a  

^a MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Complications; Diagnosis; IPT; Malaria; Plasmodium falciparum; Rapid diagnostic tests; Treatment

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; AMODIAQUINE PLUS FANSIDAR; ANTIMALARIAL AGENT; ARTEKIN; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ARTESUNATE PLUS MEFLOQUINE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; DIAZEPAM; DIHYDROARTEMISININ PLUS PIPERAQUINE; FANSIDAR; GLUCOSE; HALOFANTRINE; INSECTICIDE; LORAZEPAM; MALARIA VACCINE; MEFLOQUINE; PARALDEHYDE; PHENOBARBITAL; PHENYTOIN; PYRIMETHAMINE; QUININE; SULFADOXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACIDOSIS; ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; ANEMIA; BACTEREMIA; BED NET; BLOOD TRANSFUSION; CHILD; CLINICAL TRIAL; COMA; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG POTENTIATION; DRUG WITHDRAWAL; FEVER; FLUID THERAPY; HEART ARRHYTHMIA; HEPATITIS; HUMAN; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; IMMUNE RESPONSE; INFECTION CONTROL; LOADING DRUG DOSE; MALARIA; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; PLASMODIUM FALCIPARUM; QT PROLONGATION; REVIEW; SEIZURE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TINNITUS; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; MALARIA FALCIPARUM; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIMALARIALS; CHILD; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME;

EID: 33947713706     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.1.141     Document Type: Review

References (71)

1. Sina B. Focus on Plasmodium vivax. Trends Parasitol. 18(7), 287-289 (2002).
2. Lopez AD, Mathers CD, Ezzati M et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367(9524), 1747-1757 (2006).
3. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64(1-2 Suppl.), 1-11 (2001).
4. Snow RW, Omumbo JA, Lowe B et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 349(9066), 1650-1654 (1997).
5. Snow RW, Craig M, Deichmann U et al. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull. World Health Organ. 77(8), 624-640 (1999).
6. Newton CR, Taylor TE, Whitten RO. Pathophysiology of fatal falciparum malaria in African children. Am. J. Trop. Med. Hyg. 58(5), 673-683 (1998).
7. Bell D, Wongsrichanalai C, Barnwell JW. Ensuring quality and access for malaria diagnosis: how can it be achieved? Nat. Rev. Microbiol. 4(9 Suppl.), S7-S20 (2006).
8. Baird JK. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann. Trop. Med. Parasitol. 92(4), 367-390 (1998).
9. Murray CK, Bell D, Gasser RA et al. Rapid diagnostic testing for malaria. Trop. Med. Int. Health 8(10), 876-883 (2003).
10. Giha HA, Elbasit IE, Elgadir TM et al. Cerebral malaria is frequently associated with latent parasitemia among the semi-immune population of eastern Sudan. Microbes Infect. 7(11-12), 1196-1203 (2005).
11. Biritwum RB, Welbeck J, Barnish G. Incidence and management of malaria in two communities of different socio-economic level, in Accra, Ghana. Ann. Trop. Med. Parasitol. 94(8), 771-778 (2000).
12. Reyburn H, Mbatia R, Drakeley C et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. Br. Med. J. 329(7476), 1212 (2004).
13. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J. Infect. Dis. 184(6), 770-776 (2001).
14. Plowe CV, Kublin JG, Dzinjalamala FK et al. Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. Br. Med. J. 328(7439), 545 (2004).
15. Price RN, Uhlemann AC, Brockman A et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364(9432), 438-447 (2004).
16. Sowunmi A, Falade CO, Oduola AM et al. Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 92(4), 446-448 (1998).
17. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J. R. Soc. Med. 83(2), 82-85 (1990).
18. Clarke JB, Neftel K, Kitteringham NR et al. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int. Arch. Allergy Appl. Immunol. 95(4), 369-375 (1991).
19. Wilairatana P, Kyle DE, Looareesuwan S et al. Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. Ann. Trop. Med. Parasitol. 91(2), 125-132 (1997).
20. Nzila A, Ochong E, Nduati E et al. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans. R. Soc. Trop. Med. Hyg. 99(5), 341-346 (2005).
21. Watkins WM, Sibley CH, Hastings IM. The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. Am. J. Trop. Med. Hyg. 72(2), 163-173 (2005).
22. White NJ. Antimalarial drug resistance. J. Clin. Invest. 113(8), 1084-1092 (2004).
23. Jambou R, Legrand E, Niang M et al. Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366(9501), 1960-1963 (2005).
24. Nosten F, van VM, Price R et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356(9226), 297-302 (2000).
25. Price RN, Nosten F. Luxemburger C et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347(9016), 1654-1658 (1996).
26. Drakeley CJ, Akim NI, Sauerwein RW et al. Estimates of the infectious reservoir of Plasmodium falciparum malaria in The Gambia and in Tanzania. Trans. R. Soc. Trop. Med Hyg. 94(5), 472-476 (2000).
27. Sisowath C, Stromberg J, Martensson A et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis. 191(6), 1014-1017 (2005).
28. Duraisingh MT, Roper C, Walliker D et al. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium filciparum. Mol. Microbiol. 36(4), 955-661 (2000).
29. Price RN, Uhlemann AC, van VM et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42(11), 1570-1577 (2006).
30. Mutabingwa TK, Anthony D, Heller A et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365(9469), 1474-1480 (2005).
31. Piola P, Fogg C, Bajunirwe F et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 365(9469), 1467-1473 (2005).
32. Karema C, Fanello CI, Van OC et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Tans. R. Soc. Trop. Med. Hyg. 100(12), 1105-1111 (2006).
33. Obonyo CO, Juma EA, Ogutu BR et al. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. Trans. R. Soc. Trop. Med. Hyg. 101(2), 117-126 (2007).
34. Newton PN, McGready R, Fernandez F et al. Manslaughter by fake artesunate in Asia - will Africa be next? PLoS Med. 3(6), E197 (2006).
35. Barnes KI, Little F, Smith PJ et al. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80(6), 582-596 (2006).
36. Schellenberg D, Menendez C, Kahigwa E et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357(9267), 1471-1477 (2001).
37. Schellenberg D, Menendez C, Aponte JJ et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365(9469), 1481-1483 (2005).
38. World Health Organisation. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1), S1-S90 (2000).
39. Ackerman H, Usen S, Jallow M et al. A comparison of case-control and family-based association methods: the example of sickle-cell and malaria. Ann. Hum. Genet. 69(Pt 5), 559-565 (2005).
40. +-thalassemia protects African children from severe malaria. Blood 104(7), 2003-2006 (2004).
41. Roberts DJ, Williams T. Hemoglobinopathies and resistance to malaria. Redox Rep. 8, 304-310 (2003).
42. Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am. J. Hum Genet. 77(2), 171-192 (2005).
43. Patnaik P, Jere CS, Miller WC et al. Effects of HIV-1 serostarus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J. Infect. Dis. 192(6), 984-991 (2005).
44. French N, Nakiyingi J, Lugada E et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 15(7), 899-906 (2001).
45. Grimwade K, French N, Mbatha DD et al. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 18(3), 547-554 (2004).
46. Montgomery J, Milner DA Jr, Tse MT et al. Genetic analysis of circulating and sequestered populations of Plasmodium falciparum in fatal pediatric malaria. J. Infect. Dis. 194(l), 115-122 (2006).
47. Kaestli M, Cockburn IA, Cortes A et al. Virulence of malaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study. J. Infect. Dis. 193(11), 1567-1574 (2006).
48. Marsh K, Forster D, Waruiru C et al. Indicators of life-threatening malaria in African children. N. Engl. J. Med. 332(21), 1399-1404 (1995).
49. Taylor TE, Molyneux ME, Wirima JJ et al. Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria. N. Engl. J. Med. 319(16), 1040-1047 (1988).
50. Molyneux ME, Taylor TE, Wirima JJ et al. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q. J. Med. 71(265), 441-459 (1989).
51. Kihara M, Carter JA, Newton CR. The effect of Plasmodium falciparum on cognition: a systematic review. Trop. Med. Int. Health 11(4), 386-397 (2006).
52. Crawley J, Smith S, Kirkham F et al. Seizures and status epilepticus in childhood cerebral malaria. Q. J. Med. 89(8), 591-597 (1996).
53. Crawley J, Waruiru C, Mithwani S et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 355(9205), 701-706 (2000).
54. English M, Waruiru C, Amukoye E et al. Deep breathing in children with severe malaria: indicator of metabolic acidosis and poor outcome. Am. J. Trop. Med. Hyg. 55(5), 521-524 (1996).
55. Maitland K, Levin M, English M et al. Severe P. falciparum malaria in Kenyan children: evidence for hypovolaemia. Q. J. Med. 96(6), 427-434 (2003).
56. Maitland K, Pamba A. English M et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin. Infect. Dis. 40(4), 538-545 (2005).
57. Akech S, Gwer S, Idro R et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin. Trials 1(5), E21 (2006).
58. Phu NH, Hien TT, Mai NT et al. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N. Engl. J. Med. 347(12), 895-902 (2002).
59. Berkley JA, Lowe BS, Mwangi I et al. Bacteremia among children admitted to a rural hospital in Kenya. N. Engl. J. Med. 352(1), 39-47 (2005).
60. Graham SM, Walsh AL, Molyneux EM et al. Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. Trans. R. Soc. Top. Med. Hyg. 94(3), 310-314 (2000).
61. The Artemether-Quinine Meta-analysis Study Group. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 95(6), 637-650 (2001).
62. Dondorp A, Nosten F, Stepniewska K et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366(9487), 717-25 (2005).
63. Barennes H, Balima-Koussoube T, Nagot N et al. Safety and efficacy of rectal compared with intramuscular quinine for the early treatment of moderately severe malaria in children: randomised clinical trial. Br. Med. J. 332(7549), 1055-1059 (2006).
64. Barnes KI, Mwenechanya J, Tembo M et al. Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study. Lancet 363(9421), 1598-1605 (2004).
65. Karunajeewa HA, Reeder J, Lorry K et al. Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea. Antimicrob. Agents Chemother. 50(3), 968-974 (2006).
66. Aceng JR, Byarugaba JS, Tumwine JK Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. Br. Med. J. 330(7487), 334 (2005).
67. Pussard E, Straczek C, Kabore I et al. Dose-dependent resorption of quinine after intrarectal administration to children with moderate Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 48(11), 4422-4426 (2004).
68. Ahmad S, Ellis JC, Kamwendo H et al. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. Lancet 367(9522), 1591-7 (2006).
69. Eisele TP, Lindblade KA, Wannemuehler KA et al. Effect of sustained insecticide-treated bed net use on all-cause child mortality in an area of intense perennial malaria transmission in western Kenya. Am. J. Trop. Med. Hyg. 73(1), 149-156 (2005).
70. Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/ AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443), 1411-1420 (2004).
71. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502) 2012-2018 (2005).